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Introduction
On March 9, 2017, the Canadian parliament overwhelmingly passed the Genetic Non-Discrimination Act to prevent the use of genetic 
data to deny individuals health insurance, employment, 
housing or influence their child custody or adoption 
decisions. Supporters of the law noted the reluctance 
of Canadians to take genetic tests during clinical care 
for fear of the data being used against them[1].  Canada 
is the latest country to enact such laws, but are not the 
only ones struggling to balance the risks and benefits 
of genomic based medicine. Figure 1 shows more 
than 20 countries which have population genome 
sequencing programs. As genome sequencing data 
becomes integrated into healthcare, a serious risk to 
individuals and their extended families could result from 
inadequately protecting such information. Although 
there are many technical challenges with implementation 
of national clinical genomics programs, govern ments are 
backing programs to adopt Precision Medicine due to the 
promise to save health institutions money and improve 
national eco nomic output with healthier, productive, 
longer-living populations. With Precision Medicine 
comes a tsunami of personal data that will impact our 
understanding of disease, how we can stay healthy, and 
how we deliver healthcare.
The information sources that will be used to determine 
an individual’s health and health risk will be drawn from 
two main data types:
a. Benchmarks of objective risk - Baseline genome 
sequence, and how the genes are expressed in the 
individual, i.e.,  genotype and a cumulative list of 
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irreversible conditions resulting from the genotype, 
and
b. Benchmarks of subjective risk - An omni-
channel real-world behavioural and medical data 
set (e.g. wearables, EMR, imaging, AI, etc.)  that 
allows us to quantify lifestyle, environment, 
healthcare factors that impact outcomes. 
The data management strategies that will be adopted 
by the industry will determine the efficiency with which 
the healthcare sector will transition into implementing 
precision medicine. This report aims to assess the 
views of practitioners, i.e., the data scientists, directors 
of clinical data, and IT administrators, on the future 
growth of the objective datasets, and understand the 
most pressing issues for healthcare institutions in terms 
of management of this data and its integration into the 
clinical framework. Subjective risk data is not included 
in this article due to the exponential proliferation of 
models and fragmentation of the marketplace (the reader 
is advised to view articles on the growing “wearables” 
economy[2]). 
There is an unarticulated need to have a framework 
that, at its core, will protect consumers, be fully 
interoperable within existing healthcare infrastructure 
but will not limit the speed or direction of industry 
growth and innovation. However there are several 
challenges ahead for the healthcare industry:
a. Data size - The growth of genome data alone 
is predicted to surpass Youtube, Twitter, and 
Astronomy data in size by 2022[3],  
b. Cost - There are financial implications to setting 
up and managing data centres that can handle this 
data volume,   
c. Privacy - Genome data is the ultimate blueprint 
for individuals and the information exposes 
patients to as-yet unquantifiable risk (e.g. 
insurance, employment, healthcare, etc.) 
d. Longevity - Patients are likely to live for 100+ 
years, maintaining records for a lifetime can be a 
technical challenge particularly in the context of 
variation in quality of data, long-term compatibility 
of software/hardware systems, and data storage 
models.  
These challenges mean, similar to the experiences 
of other industries (e.g. insurance, financial services, 
marketing, media etc.), data management by healthcare 
institutions needs to evolve from a fringe activity into 
a core function that drives business strategy & activity, 
creates accountability, and is used to measure success 
and impact.
Assessing the requirements and capabilities of 
healthcare IT to address these challenges will help 
determine the timing and impact of Precision Medicine 
as routine care in the healthcare sector. 
Genome Data Management
It has been conventionally accepted that sequencing 
base costs are exponentially decreasing compared to 
Moore’s law.  Moore’s law, which projects the rate of 
doubling of transistors in an integrated circuit, roughly 
reflects the linear decreasing cost for data storage 
disks. The logarithmic decrease in sequence costs, 
Figure 1. Regional Population Genome Sequence programs announced in over 20 countries. Data source: www.phgfoundation.org
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outstripping Moore’s law, has been used as an argument 
that data storage costs will be the limiting factor for 
further growth[4].  In Figure 2, we mapped the cost for 
sequencing and storage per genome (assuming 30x 
coverage, 100 GigaByte file size). What is evident from 
this data is that the current chemistry cost to sequence 
a human genome outstrips the cost for disk storage by 
1000X. The trend line for data storage cost decreases 
predictably. The sequencing chemistry cost, however, 
may plateau out, but is predicted to decrease to a “few 
hundred dollars” per genome in a few years. 
Neither the sequencing cost or storage cost depicted 
in the graph, show the true cost to generate and manage 
a genome medical record. For sequencing, factoring 
in lab costs for sample preparation & operation costs, 
data analysis and reporting, the average cost per whole 
genome record is estimated to be 10,000 USD[5]. For 
data storage, disk purchase costs are low compared to 
the operation costs (power consumption, data operations, 
personnel, etc) to manage a data center. It is estimated 
that average annual cost to manage a 100 GB record, 
maybe anywhere near $200–$400/genome record, based 
on current annual cost to run a 1 PetaByte data center, 
which is a typical size for most healthcare centers 
making initial moves into genomics data storage[6]. 
While we assume the unit IT costs amortized over a large 
& growing data center will steadily decrease gradually 
over time, the operational cost for this storage is an on-
going cost for the lifetime of the record. The overall 
cost continually increase as new records are continually 
aggregated.  
Future estimates predict a reduction in both cost to 
sequence a genome sample and the size of the genomic 
data record maintained by clinical centers. From our 
interviews of leading genome centers, the next decade 
will see a dramatic increase in genome data. By 2030, 
it is estimated 500 Million human genomes will be 
sequenced world-wide and whole genome sequencing 
will be the routine procedure due to the cost reduction 
for sample preparation and sequencing (Dr. Torsten 
Schwede, Director, SciCore, University of Basel, CH, 
and Dr. Ewan Birney, Director GA4GH, European 
Bioinformatics Institute, UK, personal communications). 
The predicted growth in number of clinical samples will 
stress the economics and efficiencies of data centers to 
manage the volume of data, despite any reductions in 
cost to sequence or size of data files. 
It is noted that commercial Cloud storage not only 
offers convenience for data management, but at a rate 
of $0.01/GigaByte/month, the static storage costs 
are low. However, cloud storage vendors have tiered 
costs connected with data transfer, CPU operations 
for analysis, and security levels, which bring the 
cost significantly higher.  These associated costs are 
included in data operations for on-site data storage 
centres. Although some facilities may opt to use 
cloud based storage, data transfer on/off cloud based 
facilities constrains data integrity and security for 100 
GigaByte records. Some vendors propose tape drives 
to enable long term storage data records, and these 
further decrease the costs.  We hypothesize that for 
the next 10 years in the clinical genomics field, patient 
genome sequence data will be analysed in multi-omic 
aggregate studies to elucidate health status biomarkers. 
Figure 2. Approximated costs to sequence and store the data for a human genome (whole genome sequence, 30X coverage, 100 
GigaBytes).
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As such, tape drives will not be the primary media as it 
is passive storage, and hurdles with cloud storage will 
make the management more complex than on-premise 
administration of the data. 
Another decision driver that is emerging in this field 
is the need for data privacy. One of the unique privacy 
challenges brought by the genome sequence data is the 
“known unknown”. Unlike medical records which hold 
only historic information at any given time, human 
genome is a database of unknown number of markers 
that are yet to be discovered. Anyone who obtains a 
copy of the identifiable raw genome data can use it to 
unlock this information about the individual as and 
when new markers are discovered. As a result, it is 
practically impossible to understand the future impact 
of information security breaches relating to genome data 
and strong safeguards will need to be in place to protect 
it. It is one of the hypothesis of this paper that data 
privacy will be a driving factor in decision making for 
management of this data. 
To ascertain the decision drivers in practice, we 
interviewed 14 people identified in organizations 
that are advancing precision medicine in clinical and 
research organizations. These individuals (CEOs, data 
scientists, clinical directors, IT managers etc.) have first-
hand knowledge for the growth of this field, with direct 
experience executing the processes in the pipeline, or 
working with vendors.  The individuals participated 
in a 30-minute interview, and subsequently were sent 
an online questionnaire to gauge relative importance 
of decision making criteria and approach to data 
management. The subject number is small but justifiably 
so because there are only a few centers that are currently 
executing whole genome sequencing programs–which 
is the testing ground for how genomics based medicine 
might be implemented in the future. These early adopters 
will ultimately set models that will be used by others 
as the innovations related to genomic medicine diffuse 
through the healthcare industry.  
The results of the interviews indicate that all par-
ticipants agree unanimously that whole genome se-
quencing will be a standard practice in healthcare 
delivery in the future. The interviewees, who worked 
directly on clinical genomics pipelines, had examples 
of individuals who benefited directly from the data they 
generated. The benefit to patients will be the impetus for 
widespread growth of genomic services in the future. 
The support from national health programs will continue 
because of the potential breakthroughs for predictive 
health biomarkers and the overall decrease in medical 
expenditures with more accurate diagnosis. 
The current limitations experienced by all the cen-
tres interviewed, is insufficient biomarkers linking 
genotypic mutations to phenotype, or treatment options, 
limiting the number of patients that can benefit from 
this information. Thus, a critical hurdle in the delivery 
of the genomic testing in the clinic is interpreting the 
genetic information. The most time-consuming part 
of the pipeline is the manual curation of the patient’s 
genome data. Because of a lack of definitive genotype-
phenotype correlations, some cases require further 
testing to validate the genotype, and in other cases, it is 
difficult to identify any variant for clinical follow-up. 
The fix for these limitations is to continue to populate 
databases with enriched meta information about patients, 
and to facilitate means to share these findings for clinical 
decision making.  Indeed, as databases grow, facilitating 
researchers access to these genomes for population 
studies will elucidate new biomarkers. 
The second insight from interviews was that the size 
of the genome data files is a critical concern for all 
interviewees who managed or interacted with IT issues. 
The need to store a 100 Gigabyte file has meant that 
most of the institutions have setup data centres reaching 
PetaBytes in size. Because the research community 
is actively using this data, some of the growth was in 
secondary analysis and storage of genome information 
related to research methodology. The data sizes are 
already getting difficult to manage, and one center went 
as far as to suggest that they are considering deleting 
the full genome data, once the relevant data is extracted, 
and saving only the bio-sample (e.g. patient’s blood, 
or tissue). The intention is that, because sequencing is 
getting cheaper, the bio-sample can be sequenced again 
when the data is required.  The limitation here is that if 
the sample is damaged by loss of freezing, the loss is 
permanent, and irreversible   There was an interesting 
split between the European and North American 
interviewees with regards to cloud based or on-premises 
data storage.  The strong privacy rules in Europe meant 
that data cannot be held on public cloud infrastructure. 
However, the North American participants (n = 3), were 
approving of, or already testing public cloud storage for 
genome data. 
To follow-up, the interviewees participated in a 
short on-line survey to quantify criteria for how they 
would setup operations. All the participants choose data 
security as the more important factor when choosing to 
setup a clinical genomics facility. The next 3 factors, 
in order of importance, were ease of operations, low 
overhead costs, and purchase price. This is interesting 
because, during the interviews, considerations for data 
privacy weighed heavily on the operations of the facility, 
and the on-line survey verified this observation. If 
data security is a driving decision making criteria, we 
are approaching a critical point where the associated 
data management costs are the controlling factor over 
whether genetic mapping/genomic testing can become 
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scalable. The need for data privacy, concomitant with the 
societal need to study these genomes to find lifesaving 
markers for human diseases, poses challenges that are 
largely unique to healthcare. This cannot take place 
without significantly changing the approach to data 
management. Here we consider several factors that can 
enable building a framework for managing the privacy 
of personal genomes, decrease associated storage costs 
by streamlining data management operations, and, at the 
same time, facilitate the industry moving forward. 
Working towards a common national (or international) 
data management framework would go a long way to 
facilitate the practice of precision medicine. Considering 
the conflicting needs for the different stakeholders, a 
new data architecture model is proposed below for how 
all of the stakeholders, in particular, patients, physicians 
and scientists, can interact with genomic data.  (N.B. The 
framework could be employed for any type of healthcare 
data.)
Liberating Genome Information for 
Precision Medicine
When genome sequencing and precision medicine 
becomes a routine practice, a number of new challenges 
are likely to emerge, including ensuring the safety of 
the genome data whilst making the clinically valuable 
information available and locating and accessing 
patients’ marker information where sequencing is done 
by a multitude of providers.
Figure 3 below outlines a potential high-level archi-
tecture to help address some of these challenges and 
enable practicing precision medicine as part of routine 
healthcare. The proposed architecture includes four key 
components implemented at two different levels:
Sequencing Provider Level
Genome Vaults: These are highly secure (both physically 
and digitally) facilities controlled by sequencing 
providers. Made up of data processing and storage 
facilities as well as interlinked sampling equipment, 
these Genome Vaults sample, sequence, store, and 
analyse citizens’ genomes for all known markers. Once 
all known markers are identified, a citizen specific 
report is published to the Report Library hosted by the 
sequencing provider. The report essentially contains a 
list with presence or absence of all known markers in the 
citizen’s genome.
When a new marker is discovered, all genomes hosted 
in the vault are re-processed to search for this marker 
and all reports in the report library are updated.
In an ideal scenario, each citizen would only have a 
single copy of their raw genome data hosted by a trusted 
provider.
Consent Engine: The Consent Engine, hosted by the 
citizen’s trusted sequencing provider, holds all consent 
given by the citizen past and present. Granular consent 
levels enable the citizen to provide generic consent, such 
as “disclose all marker information to all valid clinical 
providers” or specific consent given in response to a 
request such as “disclose ovarian cancer risk markers to 
Dr X just this once”.
Consent Engines can also be used to record citizens’ 
consent to participate in genome research. 
Report Libraries: Report Libraries contain a list of 
all known markers for each citizen whose genome is 
deposited in the sequencing provider’s Genome Vault. 
On request from a clinician and subject to citizen’s 
consent, the presence or absence of the marker is 
confirmed to the clinician. Report Libraries are also 
accessible to citizens to review their own reports.
Each time a new report is published, the Report 
Library also sends a consent request to the citizen. 
This acts a notification to the patient to review any new 
information as well as a reminder to update any existing 
generic consent.
To avoid accidental disclosure, the Report Engine will 
need to reject any requests for marker information where 
the citizen’s consent to provide the information is older 
than the date the marker was identified.
National Level
Request Engine: A national component will also be 
required to hold a registry of all citizens who have 
genome sequences, together with the details of the 
trusted sequencing provider that holds this information. 
The Request Engine will handle all marker information 
requests from authorised clinicians practicing precision 
medicine and will keep an audit trail of all requests, 
responses and the citizen’s consent at the time of the 
response.
The Request Engine also facilitates citizen’s access to 
their marker reports either for review or for using this 
information to receive care outside national boundaries.
Facilitating Genome Research
This new approach can also be further developed to 
significantly increase the speed and accuracy of genome 
research with some modifications as outlined in Figure 
4, particularly where there is a national shared clinical 
record either in full or in summary form. To preserve 
the patient’s privacy and trust, a safe pseudonymisation 
function would need to be added to the Request Engine 
which would also facilitate the identification of the 
subject cohort and coordination of the responses from 
various sequencing providers. Sequencing providers 
would also need to host specific functionality to manage 
requests and responses which we called the Research 
Engine. Use of pseudonymisation would require 
Genomics vault: A framework for precision medicine data management 
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Figure 3. Patient and Clinician information flow with a "Genome Vault" architecture.
strong safeguards to be in place for approving research 
boundaries and associated queries to protect against 
malicious or unintentional identification of citizens.
Facilitating Genome Research
This new approach can also be further developed to 
significantly increase the speed and accuracy of genome 
research with some modifications as outlined in Figure 
4, particularly where there is a national shared clinical 
record either in full or in summary form. To preserve 
the patient’s privacy and trust, a safe pseudonymisation 
function would need to be added to the Request Engine 
which would also facilitate the identification of the 
subject cohort and coordination of the responses from 
various sequencing providers. Sequencing providers 
would also need to host specific functionality to manage 
requests and responses which we called the Research 
Engine. Use of pseudonymisation would require strong 
safeguards to be in place for approving research bound-
aries and associated queries to protect against malicious 
or unintentional identification of citizens.
In this scenario, after obtaining necessary approvals, 
the scientist provides a query with the acceptance criteria 
for the research cohort (i.e., males who have had their 
first heart attack before the age of 30) and a request for 
identifying a specific genetic marker.
The Request Engine then sends the national Shared 
Clinical Record a list of citizens who are known to 
have sequencing providers and obtains a list of subjects 
who fit the criteria. When the Shared Clinical Record 
responds with a list of citizens who fit the criteria, the 
Request Engine assigns each citizen a pseudoidentifier 
unique to the specific research. The Request Engine 
then sends a genetic marker request to each sequencing 
provider with the list of citizens against which the 
marker should be checked.
After receiving the research request, each provider’s 
Research Engine checks the citizen’s consent for research 
and compiles a work schedule for each consented citizen. 
To preserve the Genome Vault’s “outbound traffic 
only” principle, the provider’s scientists work within 
the Genome Vault and use the schedule to check each 
genome against the requested marker. They then publish 
a report to the Research Engine with the presence or the 
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Figure 4. Research information flows to study aggregated patient genome data from Genome Vaults.
absence of the marker. When all the genomes within 
the work schedule are received from the Genome Vault, 
the Research Engine sends a final report to the Request 
Engine with the requested genetic marker information. 
This report only uses the pseudoidentifiers and does not 
include the citizen’s identity
The Request Engine, compiles the responses from all 
sequencing providers and sends the final report to the 
scientist using pseudoidentifiers. The scientist can use 
these pseudoidentifiers for the duration of their research 
to ask specific questions about the individual citizens 
within the cohort without knowing their identity. Once 
the research project is closed, the Request Engine would 
delete all pseudonymisation information irretrievably. 
There are other components that we have not included 
in our diagrams such as identity management and access 
control systems that will be required for the safe and 
secure operation of this architecture. Where there is a 
national initiative for sharing clinical information across 
the healthcare system, these are likely to be in place 
already in some shape or form and there are obvious 
benefits to sharing the overlapping components between 
the two architectures as well as enabling information 
exchange between these using an agreed standard, such 
as HL7. Where this is the case, if there is enough public 
trust in national structures, it would also be beneficial 
to implement the Consent Engine at a national level 
to include all consent to share medical records and to 
participate in research.
Moving Forward
The basic framework presented here does not cover all 
the details for the functioning elements of this platform. 
For example, it would be imperative that sequencing 
centers setup their operations to directly deposit the 
clinical sequence data into the “Genomics Vault”. The 
utility of the vault functions to protect the data–which, 
from our opinion, is the “common currency” at the 
core of the discussion. This will facilitate the clinical 
genomics field to move forward by empowering more 
participants to opt-in to genetic testing, and enable more 
research discoveries from the rich diversity of the data. 
Failure to adequately protect this information could 
lead to societal and regulatory repercussions, hindering 
large-scale genomic research projects. Genomic tech-
nologies are making the most significant advance 
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towards precision medicine, and as other “omics” (e.g. 
proteomics, epigenetics) fields progress, the security and 
privacy standards that are developed will help integrate 
data from these new platforms. 
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